(HALO) Halozyme Therapeutics - Overview
Stock: Enzymes, Drug Delivery, Biologics
| Risk 5d forecast | |
|---|---|
| Volatility | 39.2% |
| Relative Tail Risk | -17.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.10 |
| Alpha | -9.32 |
| Character TTM | |
|---|---|
| Beta | 0.316 |
| Beta Downside | 0.362 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.92% |
| CAGR/Max DD | 0.67 |
EPS (Earnings per Share)
Revenue
Description: HALO Halozyme Therapeutics March 04, 2026
Halozyme Therapeutics, Inc. (HALO) is a biopharmaceutical company that develops and commercializes enzymes and devices. The companys core technology involves a patented recombinant human hyaluronidase enzyme (rHuPH20), which facilitates the subcutaneous delivery of injectable biologics and other therapeutic molecules. This technology addresses a common challenge in drug delivery by improving the absorption and dispersion of injected medications.
HALOs product portfolio includes Hylenex recombinant, a formulation of rHuPH20, and XYOSTED, a testosterone replacement therapy. The company also licenses its rHuPH20 technology to other pharmaceutical companies, enabling the development of co-formulated products. This licensing model is common in the biotechnology sector, allowing companies to generate revenue from their proprietary platforms without bearing the full cost and risk of developing every end product.
Examples of co-formulated products using HALOs technology include Herceptin Hylecta and Phesgo for breast cancer, and DARZALEX for multiple myeloma. These collaborations with major pharmaceutical companies, such as F. Hoffmann-La Roche, Janssen Biotech, and Bristol Myers Squibb, illustrate the broad applicability of HALOs drug delivery platform across various therapeutic areas. The biotechnology sector often relies on such strategic partnerships to accelerate product development and market access.
To gain a deeper understanding of HALOs market position and financial health, further research on ValueRay is recommended.
Headlines to watch out for
- Royalty revenue from drug collaborations drives profitability
- New drug approvals using rHuPH20 expand market reach
- Competition from alternative drug delivery systems impacts sales
- Regulatory changes for biologics affect development costs
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 316.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 2.83 > 1.0 |
| NWC/Revenue: 46.41% < 20% (prev 93.20%; Δ -46.79% < -1%) |
| CFO/TA 0.26 > 3% & CFO 651.6m > Net Income 316.9m |
| Net Debt (-133.8m) to EBITDA (964.3m): -0.14 < 3 |
| Current Ratio: 4.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (117.7m) vs 12m ago -9.08% < -2% |
| Gross Margin: 81.95% > 18% (prev 0.81%; Δ 8.11k% > 0.5%) |
| Asset Turnover: 60.87% > 50% (prev 49.20%; Δ 11.67% > 0%) |
| Interest Coverage Ratio: 46.08 > 6 (EBITDA TTM 964.3m / Interest Expense TTM 18.1m) |
Altman Z'' 4.22
| A: 0.26 (Total Current Assets 825.2m - Total Current Liabilities 177.1m) / Total Assets 2.53b |
| B: 0.02 (Retained Earnings 54.8m / Total Assets 2.53b) |
| C: 0.36 (EBIT TTM 835.3m / Avg Total Assets 2.29b) |
| D: 0.01 (Book Value of Equity 36.8m / Total Liabilities 2.48b) |
| Altman-Z'' Score: 4.22 = AA |
Beneish M -2.60
| DSRI: 1.04 (Receivables 441.3m/308.5m, Revenue 1.40b/1.02b) |
| GMI: 0.99 (GM 81.95% / 80.80%) |
| AQI: 1.46 (AQ_t 0.64 / AQ_t-1 0.44) |
| SGI: 1.38 (Revenue 1.40b / 1.02b) |
| TATA: -0.13 (NI 316.9m - CFO 651.6m) / TA 2.53b) |
| Beneish M-Score: -2.60 (Cap -4..+1) = A |
What is the price of HALO shares?
Over the past week, the price has changed by -1.34%, over one month by -10.21%, over three months by -6.94% and over the past year by -0.92%.
Is HALO a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HALO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84.5 | 33.2% |
| Analysts Target Price | 84.5 | 33.2% |
HALO Fundamental Data Overview March 20, 2026
P/E Forward = 4.7985
P/S = 5.3786
P/B = 157.464
P/EG = -2.5
Revenue TTM = 1.40b USD
EBIT TTM = 835.3m USD
EBITDA TTM = 964.3m USD
Long Term Debt = 2.14b USD (from longTermDebt, last quarter)
Short Term Debt = 710.7m USD (from shortTermDebt, two quarters ago)
Debt = 1.51b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -133.8m USD (from netDebt column, last quarter)
Enterprise Value = 8.88b USD (7.51b + Debt 1.51b - CCE 142.8m)
Interest Coverage Ratio = 46.08 (Ebit TTM 835.3m / Interest Expense TTM 18.1m)
EV/FCF = 13.78x (Enterprise Value 8.88b / FCF TTM 644.6m)
FCF Yield = 7.26% (FCF TTM 644.6m / Enterprise Value 8.88b)
FCF Margin = 46.15% (FCF TTM 644.6m / Revenue TTM 1.40b)
Net Margin = 22.69% (Net Income TTM 316.9m / Revenue TTM 1.40b)
Gross Margin = 81.95% ((Revenue TTM 1.40b - Cost of Revenue TTM 252.2m) / Revenue TTM)
Gross Margin QoQ = 77.39% (prev 84.41%)
Tobins Q-Ratio = 3.52 (Enterprise Value 8.88b / Total Assets 2.53b)
Interest Expense / Debt = 0.33% (Interest Expense 4.91m / Debt 1.51b)
Taxrate = 32.13% (150.0m / 466.9m)
NOPAT = 567.0m (EBIT 835.3m * (1 - 32.13%))
Current Ratio = 4.66 (Total Current Assets 825.2m / Total Current Liabilities 177.1m)
Debt / Equity = 30.95 (Debt 1.51b / totalStockholderEquity, last quarter 48.8m)
Debt / EBITDA = -0.14 (Net Debt -133.8m / EBITDA 964.3m)
Debt / FCF = -0.21 (Net Debt -133.8m / FCF TTM 644.6m)
Total Stockholder Equity = 341.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.81% (Net Income 316.9m / Total Assets 2.53b)
RoE = 92.67% (Net Income TTM 316.9m / Total Stockholder Equity 341.9m)
RoCE = 33.62% (EBIT 835.3m / Capital Employed (Equity 341.9m + L.T.Debt 2.14b))
RoIC = 28.22% (NOPAT 567.0m / Invested Capital 2.01b)
WACC = 5.94% (E(7.51b)/V(9.02b) * Re(7.09%) + D(1.51b)/V(9.02b) * Rd(0.33%) * (1-Tc(0.32)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -5.24%
[DCF] Terminal Value 88.29% ; FCFF base≈574.1m ; Y1≈708.2m ; Y5≈1.21b
[DCF] Fair Price = 294.8 (EV 34.65b - Net Debt -133.8m = Equity 34.79b / Shares 118.0m; r=5.94% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 31.67 | EPS CAGR: -46.20% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.44 | Revenue CAGR: 43.28% | SUE: 0.17 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.80 | Chg7d=-0.148 | Chg30d=-0.226 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-12-31): EPS=8.02 | Chg7d=-0.164 | Chg30d=-0.194 | Revisions Net=+0 | Growth EPS=+93.2% | Growth Revenue=+25.7%
EPS next Year (2027-12-31): EPS=9.85 | Chg7d=-0.019 | Chg30d=+0.031 | Revisions Net=+1 | Growth EPS=+22.9% | Growth Revenue=+12.8%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = +19.5% (Analyst 23.4% - Implied 3.9%)